98 related articles for article (PubMed ID: 31266008)
21. The majority of patients with metastatic melanoma are not represented in pivotal phase III immunotherapy trials.
Donia M; Kimper-Karl ML; Høyer KL; Bastholt L; Schmidt H; Svane IM
Eur J Cancer; 2017 Mar; 74():89-95. PubMed ID: 28335891
[TBL] [Abstract][Full Text] [Related]
22. Barriers in phase I cancer clinical trials referrals and enrollment: five-year experience at the Princess Margaret Hospital.
Ho J; Pond GR; Newman C; Maclean M; Chen EX; Oza AM; Siu LL
BMC Cancer; 2006 Nov; 6():263. PubMed ID: 17092349
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.
Larkin J; Lao CD; Urba WJ; McDermott DF; Horak C; Jiang J; Wolchok JD
JAMA Oncol; 2015 Jul; 1(4):433-40. PubMed ID: 26181250
[TBL] [Abstract][Full Text] [Related]
24. Systematic reviews of the effectiveness of day care for people with severe mental disorders: (1) acute day hospital versus admission; (2) vocational rehabilitation; (3) day hospital versus outpatient care.
Marshall M; Crowther R; Almaraz-Serrano A; Creed F; Sledge W; Kluiter H; Roberts C; Hill E; Wiersma D; Bond GR; Huxley P; Tyrer P
Health Technol Assess; 2001; 5(21):1-75. PubMed ID: 11532238
[TBL] [Abstract][Full Text] [Related]
25. Evaluating glioma therapies: modeling treatments and predicting outcomes.
Kirby S; Brothers M; Irish W; Florell R; Macdonald D; Schold C; Cairncross G
J Natl Cancer Inst; 1995 Dec; 87(24):1884-8. PubMed ID: 7494233
[TBL] [Abstract][Full Text] [Related]
26. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
Adis International Ltd
Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
[TBL] [Abstract][Full Text] [Related]
27. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.
Balar AV; Castellano D; O'Donnell PH; Grivas P; Vuky J; Powles T; Plimack ER; Hahn NM; de Wit R; Pang L; Savage MJ; Perini RF; Keefe SM; Bajorin D; Bellmunt J
Lancet Oncol; 2017 Nov; 18(11):1483-1492. PubMed ID: 28967485
[TBL] [Abstract][Full Text] [Related]
28. Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium.
Drugs R D; 2007; 8(5):321-34. PubMed ID: 17767397
[TBL] [Abstract][Full Text] [Related]
29. Participation of patients 65 years of age or older in cancer clinical trials.
Lewis JH; Kilgore ML; Goldman DP; Trimble EL; Kaplan R; Montello MJ; Housman MG; Escarce JJ
J Clin Oncol; 2003 Apr; 21(7):1383-9. PubMed ID: 12663731
[TBL] [Abstract][Full Text] [Related]
30. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer.
Bagley SJ; Kothari S; Aggarwal C; Bauml JM; Alley EW; Evans TL; Kosteva JA; Ciunci CA; Gabriel PE; Thompson JC; Stonehouse-Lee S; Sherry VE; Gilbert E; Eaby-Sandy B; Mutale F; DiLullo G; Cohen RB; Vachani A; Langer CJ
Lung Cancer; 2017 Apr; 106():1-7. PubMed ID: 28285682
[TBL] [Abstract][Full Text] [Related]
31. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW
Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419
[TBL] [Abstract][Full Text] [Related]
32. Adjunctive oral ziprasidone in patients with acute mania treated with lithium or divalproex, part 2: influence of protocol-specific eligibility criteria on signal detection.
Sachs GS; Vanderburg DG; Edman S; Karayal ON; Kolluri S; Bachinsky M; Cavus I
J Clin Psychiatry; 2012 Nov; 73(11):1420-5. PubMed ID: 23218158
[TBL] [Abstract][Full Text] [Related]
33. Limited Generalizability of Registration Trials in Hepatitis C: A Nationwide Cohort Study.
Berden FA; de Knegt RJ; Blokzijl H; Kuiken SD; van Erpecum KJ; Willemse SB; den Hollander J; van Vonderen MG; Friederich P; van Hoek B; van Nieuwkerk CM; Drenth JP; Kievit W
PLoS One; 2016; 11(9):e0161821. PubMed ID: 27598789
[TBL] [Abstract][Full Text] [Related]
34. Eligibility for phase 3 clinical trials of systemic therapy in real-world patients with metastatic renal cell cancer managed in a rural region.
Nieder C; Syed MA; Dalhaug A; Pawinski A; Norum J
Med Oncol; 2017 Sep; 34(9):149. PubMed ID: 28748331
[TBL] [Abstract][Full Text] [Related]
35. Palliative chemotherapy in elderly patients with common metastatic malignancies: A Hellenic Cooperative Oncology Group registry analysis of management, outcome and clinical benefit predictors.
Pentheroudakis G; Fountzilas G; Kalofonos HP; Golfinopoulos V; Aravantinos G; Bafaloukos D; Papakostas P; Pectasides D; Christodoulou C; Syrigos K; Economopoulos T; Pavlidis N;
Crit Rev Oncol Hematol; 2008 Jun; 66(3):237-47. PubMed ID: 18243010
[TBL] [Abstract][Full Text] [Related]
36. Eligibility criteria in randomized phase II and III adjuvant and neoadjuvant breast cancer trials: not a significant barrier to enrollment.
Filion M; Forget G; Brochu O; Provencher L; Desbiens C; Doyle C; Poirier B; DuRocher M; Camden S; Lemieux J
Clin Trials; 2012 Oct; 9(5):652-9. PubMed ID: 23060323
[TBL] [Abstract][Full Text] [Related]
37. Rubitecan: 9-NC, 9-Nitro-20(S)-camptothecin, 9-nitro-camptothecin, 9-nitrocamptothecin, RFS 2000, RFS2000.
Drugs R D; 2004; 5(5):305-11. PubMed ID: 15357630
[TBL] [Abstract][Full Text] [Related]
38. Changes in the natural history of nonsmall cell lung cancer (NSCLC)--comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990.
Wakelee HA; Bernardo P; Johnson DH; Schiller JH
Cancer; 2006 May; 106(10):2208-17. PubMed ID: 16604529
[TBL] [Abstract][Full Text] [Related]
39. ABI 007.
Drugs R D; 2004; 5(3):155-9. PubMed ID: 15139776
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
